43 results about "Cefazolin" patented technology

The invention provides feruloyl esterase and a preparing method and application thereof. A feruloyl esterase gene coming from a soil macro gene library have the nucleotide sequence and amino acid sequence shown in SEQ ID NO.1 and SEQ ID NO.2. The gene contains a tetrapeptide SXXK sequence motif which is rarely seen, and after the esterase gene is inserted into plasmid pET28a(+), the gene is transformed into escherichia coli BL21(DE3) to achieve heterogeneous expression. The molecular weight of purified recombinase (DLFae4) is 38.3 kDa. Besides, it is put forward for the first time that novel feruloyl esterase can hydrolyze penbritin, penicillin, cefazolin and other lactam antibiotics. As is shown by site-directed mutagenesis experiments, a catalysis triplet of DLFae4 is composed of serine(S11), histidine (H74) and aspartic acid (D302), and the mutation of any of serine (S11), histidine (H74) and aspartic acid (D302) can cause loss of the catalysis capability of DLFae4. DLFae4 has a high hydrolytic activity on methyl ferulate and has good heat stability. In the presence of cellulase, DLFae4 can obviously increase the amount of ferulic acid released from destarched wheat bran. Due to peculiar activities and enzymatic characteristics of novel feruloyl esterase, novel feruloyl esterase can be applied to feed, paper making, food, pharmacy and other fields.

The invention relates to a synthetic method of cefazolin acid. According to the synthetic method, 7-aminocephalosporanic acid is taken as a raw material, and is reacted with 1H-tetrazole-1-acetic acid in a solvent so as to obtain an intermediate; the intermediate is reacted with 5-mercapto-1-methyltetrazole under base catalysis at solution states without crystallization, washing, and drying so as to obtain cefazolin acid. One-pot method is adopted; the synthetic method is simple; solvent application amount is low; environmental pollution is low; product yield is high; cost is low; and the synthetic method is suitable for industrialized production.

The treatment of neurological disorders using cefazolin compositions and pharmaceutical compositions including oral dosage forms that include cefazolin compositions are described.

An antibacterial composite medicine contains ancef or its salt and beta-lactamase inhibitor (tazobactam or clavulanic acid) in Wt ratio of (1-20):(1-5). Its advnatage is high synergistic antibacterial action.

The invention discloses a purification method of cefazolin acid, and belongs to the technical field of medicines. The purification method of the cefazolin acid comprises the following steps: A, addingraw materials into purified water, controlling the temperature, adding alkali liquor to adjust the pH of a system, and stirring until the solution is clear; B, adding an organic solvent and stirring,standing for phase separation, and retaining a water phase; C, adding acetone and a buffer solution into the water phase, controlling the temperature, dropwise adding an acid solution to regulate thepH value of the system, adding a seed crystal, and carrying out primary crystal growing; D, adding purified water, dropwise adding an acid solution to adjust pH, cooling and secondarily growing crystals; and E, filtering to obtain a filter cake, washing the filter cake at first, drying the filter cake under vacuum and discharging to obtain the purified cefazolin acid. The purified cefazolin acidobtained by the purification method not only meets the requirement of preparation of the cefazolin acid by a subsequent freeze-drying method, but also can be applied to preparation of high-content cefazolin acid standard substances.

The invention discloses a method for preparing 7-phenylacetyl amino-3-allyl-4-cefazolin acid p-methoxybenzyl acetate, and relates to the technical field of preparation of cephalosporin medical intermediates. The method comprises the following steps that 1, a compound I, sodium bromide, potassium iodide and triphenylphosphine react in a mixed solution of dichloromethane and water, and a compound III is obtained; 2, after the reaction in the step 1 is finished, a water layer in the step 1 is separated out, alkali liquor is dropwise added into an organic layer in the step 1 for reacting, and a compound IV is obtained; 3, after the reaction in the step 2 is finished, a water layer in the step 2 is separated and recycled and circularly used for the reaction in the step 1, and the addition of sodium bromide and potassium iodide is reduced; a solvent and acetaldehyde are added into an organic layer in the step 2 for a Wittig reaction, and a compound V is prepared. According to the method, after the alkali liquor is added to generate the compound IV, the water phase can be used for circulated to be applied to the next reaction, use of sodium bromide and potassium iodide is saved, and the production cost is reduced.

The invention relates to a mouse monoclonal antibody cell strain for resisting both amoxicillin and ampicillin, belonging to the technical field of B cell hybridoma. The mouse monoclonal antibody cell strain for resisting the amoxicillin and the ampicillin has the preservation number of CGMCC NO.2674. The monoclonal antibody aiming at the amoxicillin has 100 percent of cross reaction with the ampicillin which also belongs to the penicillin antibiotics, and has no cross reaction with cefazolin of cephalosporin antibiotics. The invention can be used for rapidly detecting the residual condition of the amoxicillin and the ampicillin in animal-sourced food, and can be further used for developing an immunity detection product rapidly and accurately detecting the amoxicillin and the ampicillin in the animal-sourced food.

The invention discloses application of ursolic acid in inhibiting growth of multi-drug-resistance enterobacter cloacae. According to a good in-vitro killing function of ursolic acid upon anthropogenic multi-drug-resistance enterobacter cloacae which resists to cefazolin, cefotaxime, aupmentn, meropenem, ofloxacin, levofloxacin, ciprofloxacin, cefoxitin, minocycline, imipenem, piperacillin, azithromycin and macrodantin, growth of multi-drug-resistance enterobacter cloacae can be inhibited, the lowest sterilization concentration is 0.6mg/mL, and the lowest antibacterial concentration is 0.3mg/mL. The invention discloses an inhibition function of the ursolic acid upon the multi-drug-resistance enterobacter cloacae, and the ursolic acid is capable of effectively alleviating or solving the drug-resistance infection problem of the multi-drug-resistance enterobacter cloacae and reducing the case fatality rate, provides new ideas for inhibiting anthropogenic multi-drug-resistance enterobacter cloacae, and has great practical significances.

The invention discloses a pehanorm salt or hydrate with chemical formula as picture (1) and drug composition and application to treat bacterial infection, which comprises the following parts: cefuroxime oxtatromethane, cepham qusong tromethane, cepham thiotepa tromethane, cefoperazone tromethane, cephalothin tromethane, cefotaxime tromethane, cefolading tromethane, cefonixin tromethane, cefameizin tromethane, cefadizine tromethane, cefuroxime tromethane, cefazolin tromethane, cefapamine tromethane, cefazoline tromethane, cefaadid tromethane, cefaoxofluoride tromethane, cefaminol tromethane and their hydrate.

The invention relates to a composition of amino-cephalosporanic acid and arginine, which is characterized in that amino-cephalosporanic acid in the composition comprises cefazolin acid, cefuroxime acid, cefamandole nanfate nitrosate, cefonicid acid and cefotetan acid, and one of the above amino-cephalosporanic acids is combined with arginine to obtain the composition. The invention comprises the following steps: in gnotobasis, scaling asepsis arginine and above amino-cephalosporanic acid which have suitable granularity and specific gravity according to ratio of recipe to serve as asepsis bulkdrugs; pouring the drugs into a mixer to operate according to the standard powder mixing operating instruction; after evenly mixed, discharging and slit charging. The composition of the invention solves the problems that sodium salt agent widely applied in cephems drugs specifically has poor crystal form, solution color is easily out of limits, no bacteria exist or pyrogen is not qualified, wateris hard to control, stability is poor and the like. The invention is predicted to have important clinic application value.

An oil-in-water compound antimicrobial cefazolin nanoemulsion medicine is a nanoemulsion medicament with cefazolin and an aqueous clove extract as effective components, and comprises the following components in parts by weight: 1-15 parts of cefazolin, 10-30 parts of a surfactant, 0-25 parts of a co-surfactant, 1-10 parts of aqueous clove extract, 1-20 parts of oil and 20-70 parts of distilled water. By compounding the cefazolin and the aqueous clove extract, the oil-in-water compound antimicrobial cefazolin nanoemulsion medicine is good in medicinal effect and good in antimicrobial effect; a preparation method is very simple; the oil-in-water compound antimicrobial cefazolin nanoemulsion medicine is easier to popularize.

The invention discloses an application of citral in inhibiting growth of multi-drug resistant enterobacter cloacae. The citral can inhibit growth of multi-drug resistant enterobacter cloacae as the citral has relatively good in vitro killing action to multi-drug resistant enterobacter cloacae resisting cefazolin, cefotaxime, augmentin, meropenem, ofloxacin, levofloxacin, ciprofloxacin, cefoxitin, minocyline, imipenem, piperacillin, azithromycin, macrodantin, sulfamethoxazole and nalidixic acid. The minimum bactericidal concentration is 1.6 mg/mL and the minimal inhibitory concentration is 1.0 mg/mL. The invention provides inhibiting action of citral to multi-drug resistant enterobacter cloacae and the citral has wide application value in the field of medicine.

The invention discloses a staphylococcus drug resistance inducing method. The staphylococcus drug resistance inducing method comprises (1) selection of staphylococcus strains, (2) screening of antibiotics, (3) solution preparation of standard antibiotics, (4) measurement of minimal inhibitory concentration through a microdilution broth method, (5) passage induction, and (6) measurement of drug resistance of every generation of staphylococcus to cefazolin. According to the staphylococcus drug resistance inducing method, instruments and equipment required by experimental operation can be reduced, and subsequent material processing difficulty can be greatly reduced. Therefore, the staphylococcus drug resistance inducing method can well solve the problems on operation difficulty and costs, andmeanwhile improve the induction efficiency, accuracy and success rate. Compared with other methods, the staphylococcus drug resistance inducing method is more convenient to operate and easier to grasp.

The invention discloses a preparation method of 3-methylol cefazolin. The preparation method comprises the following steps of dropwise adding a 7-ACA solution to a 1H-tetrazole-1-acetic acid anhydridemixing solution, performing a condensation reaction, after the reaction, adjusting pH phase splitting, then adding purified water, performing phase splitting, combining water phases, then adding an organic solvent for phase splitting, and performing concentration to obtain a primary purified water phase and a secondary purified water phase; and after adjusting pH of the secondary purified water phase, adding cephalosporin-C deacetylase, then adding a dispersing agent to the filtered water phase, then reducing the temperature, performing filtration after crystal formation, performing washing,and performing drying until the moisture is smaller than 1.0%. According to the preparation method disclosed by the invention, a traditional strong basic hydrolysis technology is substituted, waste water discharge can be reduced by 80%, the cephalosporin-C deacetylase after enzymolysis can be in cyclic utilization, solvent remains are smaller than 5%, the concentration weight reduction ratio is 2%-5%, the influence of various solvents on the enzymatic activity of the cephalosporin-C deacetylase is thoroughly eliminated, the consumption of enzymes and the activity of the enzymes being utilizedonce again are guaranteed, the cost is reduced, the reaction condition is mild, the conversion rate of products is as high as 90% or above, the purity of the products is not less than 98%, and subsequent structure elucidation and pharmacological research are facilitated.

The invention relates to a plaster for treating skin stubborn dermatitis. The plaster is prepared from the following raw materials: medical vaseline, liquid paraffin, lanolin, dried alum, chlortrimeton, dexamethasone, borneol, white pepper and cefazolin. The invention has the advantages as follows: the plaster can treat various skin stubborn dermatitis diseases, such as tinea manuum and beriberi,neurodermatitis, eczema, psoriasis, tinea versicolor, decrustation of hands and feet, verruca vulgaris, impetigo, yellow-water sores, dermatitis rhus, acute universal eczema, herpes simplex, chilblain, syphilis, chancre, nucha carbunde, scldhed, snake-head furuncle, snake venom, herpes zoster, pustule, scabies, universal eczema, pityriasis simplex, rotten feet, fungal infection of the hand, innominate inflanunatory of unknown origin, burn due to hot liquid or fire, incised wound, incised wound and genital herpes in sexually transmitted diseases, has efficacy of killing parasites to relieve itching, removing necrotic tissue to promote tissue regeneration, detoxifying and dispelling cold and dispelling wind and eliminating dampness, and is less in dosage, quick in effectiveness and convenient to use.

Disclosed herein are methods and drug compositions for treating Lyme disease and post-treatment Lyme disease syndrome (PTLDS) or chronic Lyme disease (CLD). In one embodiment, a method of treating a subject with Lyme disease involves administering an effective amount of a therapeutic agent selected from the group consisting of tetraethylthiuram disulfide, doxorubicin, epirubicin, azlocillin, cephalothin, josamycin, cefotaxime, cefazolin, erythromycin, calcimycin, gramicidin, cefdinir, gambogic acid, ceftazidime, ticarcillin, valinomycin, moxifloxacin, linezolid, idarubicin, tosufloxacin, loratadine, ceftriaxone, and combinations thereof, and pharmaceutical salts, hydrates, and solvates thereof.

The invention discloses an application of pulsatilla saponin A3 in inhibiting the growth of multi-drug-resistant Providencia rettgeri. According to the invention, the pulsatilla saponin A3 has good in-vitro killing effect on human-derived Providencia rettgeriis with resistance to ampicillin, ampicillin/sulbactam, cefazolin, cefotetan, ceftriaxone, ceftazidime, tobramycin, piperacillin tazobactam,ciprofloxacin, levofloxacin, amikacin, compound phenoxymine, cefepime, ertapenem, imipenem, aztreonam and gentamicin, can inhibit in-vitro growth of the multi-drug-resistant Providencia rettgeri, andhas a minimum inhibitory concentration of 125 [mu]g/mL and a minimum bactericidal concentration of 250 [mu]g/mL. The pulsatilla saponin A3 provided by the ivnention has an antibacterial effect on themulti-drug-resistant Providencia rettgeri, can relieve or solve the problem that the drug resistance of the multi-drug-resistant Providencia rettgeri is increased, and provides a theoretical basis forclinical antibacterial treatment and novel drug research and development.

The invention discloses application of luteolin in inhibiting the growth of multi-drug resistant enterobacter cloacae. Luteolin has a good in-vitro killing effect on multi-drug resistant enterobactercloacae with resistance to cefazolin, cefotaxime, augmentin, meropenem, ofloxacin, levofloxacin, ciprofloxacin, cefoxitin, minocycline, imipenem, piperacillin, azithromycin, furantoin, sulfamethoxazole and nalidixic acid, can inhibit the growth of the multi-drug resistant enterobacter cloacae, and has a minimum bactericidal concentration of 0.5mg/mL and a minimum inhibitory concentration of 0.3mg/mL. The invention provides the inhibition effect of luteolin on the multi-drug resistant enterobacter cloacae, and has wide application value in the fields of medicine and the like.

The invention discloses application of vanillic acid in inhibiting growth of multi-drug-resistance staphylococcus aureus. The inhibition effect of the vanillic acid on humanized multi-drug-resistancestaphylococcus aureus is put forward based on the fact that the vanillic acid has a good in-vitro killing effect on humanized multi-drug-resistance staphylococcus aureus which is resistant to linezolid, trimethoprim, gentamicin, ciprofloxacin, penicillin, cefazolin, clindamycin, vancomycin, oxacillin and piperacillin, and can inhibit the growth of multi-drug-resistance staphylococcus aureus, wherein the minimum bactericidal concentration is 2.4 mg/mL, and the minimum inhibitory concentration is 0.3 mg/mL. By means of the vanillic acid, drug-resistance infection of multi-drug-resistance staphylococcus aureus can be effectively relieved or solved, the mortality is reduced, a new idea is put forward for inhibition of humanized multi-drug-resistance staphylococcus aureus, and the vanillic acidhas important practical significance.

The invention discloses a pharmaceutical compound preparation for treating staphylococcal pneumonia. The pharmaceutical compound preparation for treating staphylococcal pneumonia is prepared from thefollowing components in parts by weight: 10 to 300 parts of cefazolin, 10 to 120 parts of amikacin and 10 to 1,600 parts of a medicine carrier, wherein the cefazolin and the amikacin which are used asmedicine compositions are mixed with the medicine carrier to form the compound preparation. The invention provides the cefazolin and amikacin pharmaceutical compound preparation for treating the staphylococcal pneumonia, which is convenient to take and safe to use; the pharmaceutical compound preparation is outstanding in therapeutic effect, reduces complications to an extremely large extent, causes fewer sequel, generally has no side effects, and can help a patient to get well quickly.

The invention discloses application of citral in inhibition of growth of multi-drug resistant providencia rettgeri. The citral has better in-vitro killing effects on human-derived providencia rettgeriresisting ampicillin, ampicillin/sulbactam, cefazolin, cefotetan, ceftriaxone, ceftazidime, tobramycin, tazobactam and piperacillin, ciprofloxacin, levofloxacin, amikacin, cotrimoxazole, cefepime, ertapenem, imipenem, aztreonam and gentamicin, can inhibit growth of resistant providencia rettgeri, and has the minimum bactericidal concentration of 0.5 mg/mL and the minimum inhibitory concentrationof 0.25 mg/mL; and the inhibition function of the plant extract citral on the multi-drug resistant providencia rettgeri can relieve or solve the problem of increase of drug resistance of the multi-drug resistant providencia rettgeri and provide a theoretical basis for clinical antibacterial treatment and research and development of novel drugs.

The invention provides a composite medicine comprising cefazolin, which is prepared from the following active ingredients: cefazolin, vitamin C, propylene glycol and lidocaine at a fraction ratio of (63-130):(6-12):(12-40):(15-36). The invention also provides a preparation method of the composite medicine. The composite medicine provided by the invention is superior to the prior art in safety, stability and therapeutic effect, and the preparation method is energy-saving and environment-friendly.

The invention provides a method for simultaneously determining the contents of seven antibiotics in a water sample. The method comprises the following steps: centrifuging the water sample, taking the supernate, and conducting filtering to obtain a pre-treated sample; carrying out solid-phase extraction on the pretreated sample through an activated Poly-Sery HLB (Hydrophile-Lipophile Balance) column, so as to obtain an enriched concentrated solution; and performing ultra-high performance liquid chromatography gradient elution on an enriched concentrated solution by taking acetonitrile and 5% acetic acid as mobile phases and taking a chromatographic column as Poroshell 695975-902T EC-C18, and performing ultraviolet spectrum detection to obtain chromatograms of the contents of the seven antibiotics, thereby obtaining the contents of the seven antibiotics. According to the technical scheme, solid-phase extraction and ultra-high performance liquid chromatography are combined, the content of the seven kinds of cephalosporin antibiotics including ceftizoxime, cefixime, cefathiamidine, cefazolin, cefodizime, cefuroxime and cefoxitin can be detected at the same time, detection is rapid, the result is accurate, and the cost is low.